

AİLEVİ AKDENİZ ATEŞLİ BİR OLGUDA C1-İNİHİTÖR EKSİKLİĞİ

Harun Peru¹, Ahmet Midhat Elmacı¹, Fatih Akın²

ÖZ:

C1 inhibitör (C1-INH) eksikliği ilk kez 1881 yılında tanımlanmıştır. Hastalığın prevalansının 1/50000 olduğu tahmin edilmektedir. C1-INH eksikliği nadir görülmesine rağmen, birçok hastalığın seyri sırasında da gelişebilmektedir. On yaşında kız hasta hastanemize yüzünde ve ellerinde sislik ve karın ağrısı şikayetiyle başvurdu. Hasta beş yıl önce ailevi Akdeniz ateşi (FMF) tanısı almıştı ve kolsisin tedavisi kullanılmıyordu. Ellerinde ve yüzündeki sislikler üç yıldır bir ya da iki ayda bir kere oluyor ve 2 gün içinde kendiliğinden düzeliyordu. Laboratuvar incelemelerinde kompleman C4 seviyesi 5mg/dl (normal sınırlar: 10-40mg/dl), C1-INH düzeyi 0,08 g/L (normal sınırlar: 0,15-0,35 g/L) idi. Hastaya C1-INH eksikliği tanısı konuldu. Traneksamik asit tedavisi başlandı. Hastanın altı aylık takibi süresince, sadece bir kez hafif bir anjiödem atağı görüldü. Bildiğimiz kadarı ile C1-INH eksikliği ve FMF birlikteliği daha önceden bildirilmemiştir. Bu yazıda FMF seyri sırasında C1-INH eksikliği tespit edilen bir olgu sunulmuştur.

Anahtar Kelimeler: C1 İnhibitör Eksikliği, Ailevi Akdeniz Ateşi

A CASE OF C1-INHIBITOR DEFICIENCY WITH FAMILIAL MEDITERRANEAN FEVER

ABSTRACT

The clinical syndrome caused by C1-inhibitor (C1-INH) deficiency was first described in 1881. The prevalence of the disease has been estimated to be 1/50,000. Although it is a rare disorder, C1-INH deficiency may develop during the course of diverse diseases. A 10-year-old girl was referred to our hospital because of swelling on her face and hands and abdominal pain. She had been diagnosed with familial Mediterranean fever (FMF) 5 years previously and treated with colchicine. The patient had had swelling on her face and hands monthly or bimonthly since 3 years old and the symptoms had been resolving without treatment within 1-2 days. Laboratory investigations revealed that her C4 complement level was 5 mg/dl (normal range: 10-40 mg/dl) and C1-INH level was 0.08 g/L (normal range: 0.15-0.35 g/L). C1-INH deficiency was diagnosed. Treatment with tranexamic acid was started. During the follow-up for 6 months she had only one mild attack of angioedema. To our knowledge, the coexistence of C1-INH deficiency and FMF has not been previously reported. We herein present a patient with C1-INH deficiency that developed during the clinical course of FMF.

Keywords: C1-Inhibitor Deficiency, Familial Mediterranean Fever

INTRODUCTION

The clinical syndrome caused by C1-inhibitor (C1-INH) deficiency was first described in 1881¹. There are two forms of C1-INH deficiency: hereditary and acquired. Clinical manifestations of both forms are similar and characterized by the occurrence of subcutaneous and submucosal swellings in any part of the skin, and in the respiratory and in gastrointestinal tracts. In the hereditary form, symptoms usually appear early in life and are normally accompanied by a family history². Acquired C1-INH deficiency has been observed in association with lymphoproliferative disorders, malignancy, autoimmune diseases, and infections³. It primarily affects adults or elderly patients with no family history for the disease⁴.

Familial Mediterranean fever (FMF) is an autosomal recessive disorder characterized by recurrent, self-limited episodes of fever and serosal inflammation accompanied with a marked acute-phase response⁵. To our knowledge, the coexistence of C1-INH deficiency and FMF has not been previously reported. We herein present a patient with C1-INH deficiency that developed during the clinical course of FMF.

CASE REPORT

A 10-year-old girl was referred to our hospital because of swelling on her face and hands and abdominal pain. She had been diagnosed with FMF 5 years before and treated with colchicine. She had recurrent fever and abdominal pain attacks, although the other findings (arthritis, arthralgia, myalgia, erysipelas-like erythema, and pleuritis attacks) associated with FMF were absent. The patient had had swelling on her face and hands monthly or bimonthly since 3 years old and the symptoms had been resolving without treatment within 1-2 days. Her physical examination was unremarkable except for swelling on her face (Fig. 1) and her right hand (Fig. 2). Laboratory investigations revealed that her C4 complement level was 5 mg/dl (normal range: 10-40 mg/dl), C1-INH level was 0.08 g/L (normal range: 0.15-0.35 g/L), and serum amyloid-A level was 15.3 mg/dl (normal range: 0-5.8 mg/dl). Complement C3 and IgD levels were within normal limits. Antinuclear antibodies (ANA) were negative. Serum BUN, creatinine, electrolytes, complete blood count, and urine analysis were unremarkable. Abdominal ultrasound and flow cytometry analysis of peripheral blood showed no abnormalities. An E148Q homozygous mutation was identified. C1-INH deficiency was diagnosed. Treatment with tranexamic acid 30 mg/kg/day was started. During the follow-up for 6 months she had only one mild attack of angioedema.

Geliş Tarihi : 06/09/2007

Kabul Tarihi : 24/02/2009

Received : September 06, 2007

Accepted : February 24, 2009

¹Selçuk Üniversitesi, Meram Tıp Fakültesi, Çocuk Nefroloji Bilim Dalı, Konya, Türkiye

²Selçuk Üniversitesi, Meram Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Konya, Türkiye

Fig. 1. Angioedema on the face**Fig. 2.** Angioedema on the right hand

DISCUSSION

C1-INH is a serum α_2 -globulin molecule and a member of the serpin family of protease inhibitors. It primarily affects adult or elderly patients with no family history for the disease. The gastrointestinal involvement is thought to be segmental and transient with reversion to normal within several days of an attack. Abdominal pain, nausea, and vomiting are the dominant symptoms in approximately 25% of patients⁶. Acute attacks of abdominal pain can mimic surgical emergencies.

Cardinal signs and symptoms of FMF are peritonitis (93.7%), fever (92.5%), arthritis (47.4%), pleuritis (31.2%), myalgia (39.6%), and erysipelas-like erythema (20.9%).⁷ Abdominal FMF attacks resemble the clinical presentation of acute abdomen with severe abdominal pain and rigidity, and onset is sudden and acute, leading to rapid development of symptoms within 1-2 hours.

There are two forms of C1-INH deficiency: hereditary and acquired. In the hereditary form, symptoms usually appear early in life and are normally accompanied by a family history³. Acquired C1-INH deficiency has been observed in association with lymphoproliferative disorders, malignancy,

autoimmune diseases and infections². However, to our knowledge, no association between FMF and C1-INH deficiency has been previously reported. Our patient developed recurrent fever and self-limiting peritonitis attacks that were typical for FMF. Her symptoms resolved after colchicine started. She was homozygous for the E148Q mutation. The carrying of this mutation is reported to be high in healthy populations, and especially the Turkish population. Although E148Q mutation is speculated to be a polymorphism, we cannot rule out the possibility that E148Q has a disease-causing effect while many patients carrying this mutation have been reported in the literature⁸. However, during follow-up she developed clinical features of angioedema, and laboratory investigations revealed a low serum C1-INH level. Although recurrent abdominal attacks may complicate the clinical course of C1-INH deficiency, the good response to colchicine and positive MEFV gene mutation confirmed the diagnosis of FMF. Management of patients with C1-INH deficiency includes antifibrinolytics (tranexamic acid, epsilon aminocaproic acid), androgens (danazol), and C1-INH concentrates³. Treatment with tranexamic acid 30 mg/kg/day in our patient effectively reduced the attacks.

In summary, we herein reported the occurrence of C1-INH deficiency together with FMF for the first time in the literature.

Yazışma Adresi: Harun Peru

Selçuk Üniversitesi, Meram Tıp Fakültesi

Çocuk Nefroloji Bilim Dalı,

Konya, Türkiye

Tel: 0332 2237430

E-mail:harunperu@selcuk.edu.tr

REFERENCES

1. Davis AE: Hereditary and acquired deficiencies of C1 inhibitor. *Immunodeficiency Rev* 1989; 1:207-226.
2. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. *Clin Exp Immunol* 2005; 139:379-394.
3. Farkas H, Szongoth M, Bely M, et al. Angioedema due to acquired deficiency of C1 esterase inhibitor associated with leucocytoclastic vasculitis. *Acta Derm Venereol* 2001; 81:298-300.
4. Markovic SN, Inwards DJ, Frigas EA, et al. Acquired C1 Esterase Inhibitor Deficiency: Clinical review. *Ann Intern Med* 2000; 132:144-150.
5. Sohar E, Gafni J, Pras M, et al. Familial Mediterranean fever. A survey of 470 cases and review of literature. *Am J Med* 1967; 43:227-253.
6. Sim TC, Grant JA. Hereditary angioedema: its diagnostic and management perspectives. *JAMA* 1990; 88:656-664.
7. Tunca M, Akar S, Onen F, et al. Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. *Medicine (Baltimore)* 2005; 84:1-11.
8. Ben-Chetrit E, Lerer I, Malamud E, et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? *Hum Mutat.* 2000 15(4):385-386.